[Management of epithelial ovarian cancer. Short text drafted from the French joint recommendations of FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa].

Texte court rédigé à partir de la recommandation nationale de bonnes pratiques cliniques « Conduites à tenir initiales devant des patientes atteintes d’un cancer épithélial de l’ovaire » élaborée par FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY et labélisée par l’INCa ».

Journal

Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 06 01 2019
accepted: 18 01 2019
pubmed: 10 3 2019
medline: 19 4 2019
entrez: 10 3 2019
Statut: ppublish

Résumé

Faced to an undetermined ovarian mass on ultrasound, an MRI is recommended and the ROMA score (combining CA125 and HE4) can be proposed (grade A). In case of suspected early stage ovarian or fallopian tube cancer, omentectomy (at least infracolonic), appendectomy, multiple peritoneal biopsies, peritoneal cytology (grade C) and pelvic and para-aortic lymphadenectomy are recommended (grade B) for all histological types, except for the expansive mucinous subtype where lymphadenectomy may be omitted (grade C). Minimally invasive surgery is recommended for early stage ovarian cancer, if there is no risk of tumor rupture (grade B). Adjuvant chemotherapy with carboplatin and paclitaxel is recommended for all high-grade ovarian or Fallopian tube cancers, stage FIGO I-IIA (grade A). In case of ovarian, Fallopian tube or primitive peritoneal cancer of FIGO III-IV stages, thoraco-abdomino-pelvic CT scan with injection (grade B) is recommended. Laparoscopic exploration for multiple biopsies (grade A) and to evaluate carcinomatosis score (at least using the Fagotti score) (grade C) are recommended to estimate the possibility of a complete surgery (i.e. no macroscopic residue). Complete medial laparotomy surgery is recommended for advanced cancers (grade B). It is recommended in advanced cancers to perform para-aortic and pelvic lymphadenectomy in case of clinical or radiological suspicion of metastatic lymph node (grade B). In the absence of clinical or radiological lymphadenopathy and in case of complete peritoneal surgery during an initial surgery for advanced cancer, it is possible not to perform a lymphadenectomy because it does not modify the medical treatment and the overall survival (grade B). Primary surgery is recommended when no tumor residue is possible (grade B). After a complete first surgery, it is recommended to deliver 6 cycles of intravenous (grade A) or to propose intraperitoneal (grade B) chemotherapy, to be discussed with patient, according to the benefit/risk ratio. After a complete interval surgery for a FIGO III stage, the hyperthermic intra peritoneal chemotherapy (HIPEC) can be proposed in the same conditions of the OV-HIPEC trial (grade B). In case of tumor residue after surgery or FIGO stage IV, chemotherapy associated with bevacizumab is recommended (grade A).

Identifiants

pubmed: 30850152
pii: S0007-4551(19)30091-8
doi: 10.1016/j.bulcan.2019.01.014
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Phthalazines 0
Piperazines 0
Bevacizumab 2S9ZZM9Q9V
olaparib WOH1JD9AR8

Types de publication

Journal Article Practice Guideline Review

Langues

fre

Sous-ensembles de citation

IM

Pagination

354-370

Informations de copyright

Copyright © 2019 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

Vincent Lavoue (V)

CHU de Rennes, hôpital sud, service de gynécologie, 16, boulevard de Bulgarie, 35000 Rennes, France; Chemistry, oncogenesis, stress and signaling, centre Eugène Marquis, Inserm 1242, rue Bataille Flandres-Dunkerque, 35000 Rennes, France. Electronic address: Vincent.lavoue@chu-rennes.fr.

Cyrille Huchon (C)

CHI Poissy, service de gynécologie, 78300 Poissy, France.

Cherif Akladios (C)

CHU Strasbourg, hôpital Hautepierre, service de gynécologie, 67000 Strasbourg, France.

Pascal Alfonsi (P)

Hôpital Saint-Joseph, service d'anesthésie, 75000 Paris, France.

Naoual Bakrin (N)

CHU Lyon-Sud, service de chirurgie digestive, Pierre-Bénite, 69000 Lyon, France.

Marcos Ballester (M)

Groupe hospitalier Diaconesses Croix Saint Simon, service de gynécologie, 75000 Paris, France.

Sofiane Bendifallah (S)

AP-HP, institut universitaire de cancérologie Sorbonne université, service de gynécologie-obstétrique et médecine de la reproduction, hôpital Tenon, UMRS-938, 4, rue de La Chine, 75020 Tenon, France.

Pierre-Adrien Bolze (PA)

CHU Lyon-Sud, service de chirurgie gynécologique, Pierre Bénite, 69000 Lyon, France.

Fabrice Bonnet (F)

AP-HP, hôpital Tenon, service d'anesthésie, 75020 Tenon, France.

Charlotte Bourgin (C)

CHRU, hôpital Jeanne de Flandres, service de chirurgie gynécologique, 59000 Lille, France.

Nathalie Chabbert-Buffet (N)

AP-HP, institut universitaire de cancérologie Sorbonne université, service de gynécologie-obstétrique et médecine de la reproduction, hôpital Tenon, UMRS-938, 4, rue de La Chine, 75020 Tenon, France.

Pierre Collinet (P)

CHRU, hôpital Jeanne de Flandres, service de chirurgie gynécologique, 59000 Lille, France.

Blandine Courbiere (B)

AP-HM La Conception, pôle Femmes-Parents-Enfants-centre clinico-biologique d'AMP, 147, boulevard Baille, 13000 Marseille, France; Aix-Marseille université, CNRS, IRD, Avignon université, IMBE UMR 7263, 13000 Marseille, France.

Thibault De la Motte Rouge (T)

Centre Eugène Marquis, service d'oncologie médicale, 35000 Rennes, France.

Mojgan Devouassoux-Shisheboran (M)

CHU Lyon-Sud, service d'anatomo-pathologie, hospices civiles de Lyon, Pierre-Bénite, 69000 Lyon, France.

Claire Falandry (C)

CHU Lyon-Sud, service d'oncogériatrie, hospices civiles de Lyon, Pierre-Bénite, 69000 Lyon, France.

Gwenal Ferron (G)

Institut Claudius Regaud, IUCT Oncopole, service d'oncologie chirurgicale, 31000 Toulouse, France.

Laure Fournier (L)

AP-HP, service de radiologie, hôpital Européen Georges Pompidou, 75015 Paris, France.

Laurence Gladieff (L)

Institut Claudius Regaud, IUCT Oncopole, service d'oncologie médicale, 31000 Toulouse, France.

François Golfier (F)

CHU Lyon-Sud, service de chirurgie gynécologique, Pierre Bénite, 69000 Lyon, France.

Sébastien Gouy (S)

Institut Gustave Roussy, service de chirurgie, 94800 Villejuif, France.

Frédérique Guyon (F)

Institut Bergonié, service de chirurgie, 33000 Bordeaux, France.

Eric Lambaudie (E)

Institut Paoli Calmette, service de chirurgie, 13000 Marseille, France.

Alexandra Leary (A)

Institut Gustave Roussy, service d'oncologie médicale, 94800 Villejuif, France.

Fabrice Lecuru (F)

AP-HP, hôpital Européen Georges Pompidou, service de chirurgie gynécologique et oncologique, 75015 Paris, France.

Marie-Aude Lefrere-Belda (MA)

AP-HP, hôpital Européen Georges Pompidou, service d'anatomo-pathologie, 75015 Paris, France.

Eric Leblanc (E)

Centre Oscar Lambret, service de chirurgie, 59000 Lille, France.

Adrien Lemoine (A)

AP-HP, hôpital Tenon, service d'anesthésie, 75020 Tenon, France.

Fabrice Narducci (F)

Centre Oscar Lambret, service de chirurgie, 59000 Lille, France.

Lobna Ouldamer (L)

CHU de Tours, service de chirurgie gynécologique, 37000 Tours, France.

Patricia Pautier (P)

Institut Gustave Roussy, service d'oncologie médicale, 94800 Villejuif, France.

François Planchamp (F)

Institut Bergonié, service de méthodologie, 33000 Bordeaux, France.

Nicolas Pouget (N)

Curie (site Saint Cloud), service de chirurgie, 75000 Paris, France.

Isabelle Ray-Coquard (I)

Centre Léon Bérard, service d'oncologie médicale, 69000 Lyon, France.

Christine Rousset-Jablonski (C)

Centre Léon Bérard, service d'oncologie médicale, 69000 Lyon, France.

Claire Senechal-Davin (C)

Institut Bergonié, service de chirurgie, 33000 Bordeaux, France.

Cyril Touboul (C)

CHI de Créteil, service de chirurgie gynécologique, 94000 Créteil, France.

Isabelle Thomassin-Naggara (I)

AP-HP, hôpital Tenon, service de radiologie, 75020 Tenon, France.

Catherine Uzan (C)

Institut universitaire de cancérologie, Sorbonne université, hôpital Pitié-Salpêtrière, service de chirurgie et cancérologie gynécologique et mammaire, Inserm U938, 75000 La pitié, France.

Benoit You (B)

Institut de cancérologie des Hospices Civils de Lyon, service d'oncologie médicale, Pierre-Bénite, 69000 Lyon, France.

Emile Daraï (E)

AP-HP, institut universitaire de cancérologie Sorbonne université, service de gynécologie-obstétrique et médecine de la reproduction, hôpital Tenon, UMRS-938, 4, rue de La Chine, 75020 Tenon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH